Press Release: Asterias : FDA Accepts Asterias Biotherapeutics' Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program

FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that the Food and Drug Administration (FDA) has accepted its request to meet to discuss proposed next steps for the OPC1 clinical development program. The Company's Type B meeting request was made in accordance with the Regenerative Medicine Advanced Therapy (RMAT) designation under the 21st Century Cures Act.